



City Research Online

City St George's, University of London

Citation: Dwek, M-R., Newman, S. P., Brini, S., Holder, P., Machesney, M., Propper, D., Rixon, L., Hirani, S. P. & Hurt, C. S. (2023). The impact of chemotherapy on cognitive performance post-surgery in patients with colorectal cancer: A prospective cohort study. *Psycho-Oncology*, 32(7), pp. 1057-1066. doi: 10.1002/pon.6147

This is the published version of the paper.

This version of the publication may differ from the final published version. To cite this item please consult the publisher's version.


Permanent repository link: <https://openaccess.city.ac.uk/id/eprint/30495/>

Link to published version: <https://doi.org/10.1002/pon.6147>

Copyright and Reuse: Copyright and Moral Rights remain with the author(s) and/or copyright holders. Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge, unless otherwise indicated, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way. For full details of reuse please refer to [City Research Online policy](#).

ORIGINAL ARTICLE

The impact of chemotherapy on cognitive performance post-surgery in patients with colorectal cancer: A prospective cohort study

Marie-Rose Dwek¹ | Stanton P. Newman¹ | Stefano Brini¹ | Pru Holder¹ | Michael Machesney² | David Propper³ | Lorna R. Rixon¹ | Shashivadan P. Hirani¹ | Catherine S. Hurt¹ 

¹Centre for Health Services Research, School of Health and Psychological Sciences, City, University of London, London, UK

²Barts Health NHS Trust, Whipps Cross Hospital, London, UK

³Centre for Tumour Microenvironment, Barts Cancer Institute-A CRUK Centre of Excellence, Queen Mary University of London, London, UK

Correspondence

Catherine S. Hurt, Centre for Health Services Research, School of Health and Psychological Sciences, City, University of London, London EC1V 0HB, UK.

Email: Catherine.hurt.1@city.ac.uk

Funding information

Barts Charity, Grant/Award Number: 477/2313

Abstract

Objectives: Subjective reports of cognitive impairment following chemotherapy are frequent in cancer patients. Objective cognitive impairment has been observed in cancer patients regardless of treatment regimen suggesting the relationship between cognitive impairment and chemotherapy is not clear cut. Little research has explored the effects of chemotherapy on cognition following surgery in colorectal cancer (CRC). The present study explored the effects of chemotherapy on cognitive performance in a sample of CRC patients.

Methods: 136 participants were recruited into a prospective cohort study: 78 CRC patients undergoing surgery and adjuvant chemotherapy, 58 CRC patients undergoing surgery only. A battery of neuropsychological tests was administered to participants 4 weeks post-surgery (T1), 12 weeks after first chemotherapy (T2) and 3 months after last chemotherapy (T3) or equivalent time-points.

Results: Using the criterion of scoring at least two standard-deviations below the group norm on at least one neuropsychological test, 45%–55% of all CRC patients showed cognitive deficits 10 months after surgery (T3) and 14% on at least 3 tests. However, cognition did not significantly differ between patients who had chemotherapy and those who did not. A time by group interaction effect was found on the composite cognition score using multi-level modelling suggesting a greater improvement in cognition in the surgery only group over time ($p < 0.05$).

Conclusions: CRC patients display cognitive impairment 10 months after surgery. Chemotherapy did not worsen cognitive impairment but did appear to slow cognitive recovery relative to those undergoing surgery only. The findings demonstrate a clear need for supportive cognitive interventions for all CRC patients following treatment.

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2023 The Authors. *Psycho-Oncology* published by John Wiley & Sons Ltd.

KEYWORDS

cancer, chemotherapy, cognition, colorectal, impairment, oncology, surgery

1 | INTRODUCTION

Colorectal cancer (CRC) average 5-year relative survival rates have increased from 22% to 57% in the United Kingdom over the last 40 years.¹ This reduction in mortality has led to an increased focus on quality of life. Cancer and its treatments can lead to a range of side effects, which negatively impact on patient quality of life. Impairment of cognitive function is one such side effect.²

The negative effects of surgery and anaesthesia on cognition have been demonstrated in CRC patients.^{2,3} Adjuvant chemotherapy is routinely offered to CRC patients with high-risk stage II and stage III colorectal cancers to reduce the risk of local and systemic recurrence post-surgery in the United Kingdom.⁴ Chemotherapy is ideally initiated 4–8 weeks after surgery, and its effects are likely to commence whilst some patients are still recovering from the cognitive effects of surgery and anaesthesia.

Several meta-analyses have confirmed the presence of objective cognitive deficits in patients undergoing chemotherapy across a range of cancers.^{5,6} Whilst initially solely attributed to treatment with chemotherapy, hence the term 'chemobrain', it is becoming clear that a range of factors including the cancer, surgery, anaesthesia, fatigue and mood may play a role in the aetiology of cognitive impairment in cancer patients with some research indicating cognitive impairment present prior to systemic treatment.^{5,7–11}

Research in CRC is limited with few longitudinal studies available to give accurate indications of the prevalence and incidence of cognitive impairment in CRC.⁶ Existing studies suggest that CRC patients display greater cognitive impairment than matched healthy controls (43% vs 15%).¹² CRC patients exhibited impairment in attention/working memory, verbal learning/memory, and complex processing speed.¹² The relationship between chemotherapy and cognitive impairment in CRC remains unclear with research to-date presenting conflicting results, with some studies finding chemotherapy to be associated with poorer cognitive performance, but other studies finding no association.^{5,12,13}

Despite the publication of international guidelines for researching cognitive impairment in cancer survivors,¹⁴ a recent systematic review in colorectal cancer highlighted the need for future research to use standardised criteria and measures to define and assess cognitive impairment.⁵ Furthermore, the review called for more research into the relationships between emotional distress and cognitive impairment to attempt to clarify these associations.⁵

The primary objective of the present research was to explore the impact of adjuvant chemotherapy on cognitive recovery post-surgery in CRC patients, adhering to International Cognition and Cancer Task Force (ICCTF) guidelines.¹⁴ Specifically, comparing the frequency of cognitive deficits and changes in cognition over time between groups. It was hypothesised that recovery from post-surgery cognitive performance would be greater in patients who did not undergo adjuvant

chemotherapy. The secondary objective was to explore the relationships between emotional distress, fatigue and cognition.

2 | MATERIALS AND METHODS

2.1 | Design

This study is reported in accordance with the guidelines for Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.¹⁵ The data reported in this paper was taken from a prospective cohort study measuring cognition in two groups: (i) patients diagnosed with CRC who had undergone surgery 'surgery only group', (ii) patients diagnosed with CRC who had surgery followed by chemotherapy 'chemotherapy group'. A third group with no cancer history, 'learning control group', were recruited to control for learning effects on the neuropsychological tests only. Data was collected at three time-points: 'T1' (approx. 4 weeks post-surgery, prior to chemotherapy), 'T2' (12 weeks after first scheduled chemotherapy [approx. 4 months post-surgery]), 'T3' (3 months after last scheduled chemotherapy for patients receiving 6 months of treatment or 6 months after last scheduled chemotherapy for patients receiving 3 months of treatment (approx. 10 months post-surgery)). Data was collected from the surgery group at equivalent time-points.

2.2 | Procedure

A consecutive series of outpatients attending oncology clinics from five London Hospitals were invited to participate in the study between April 2014 and July 2018. Inclusion criteria: aged 18 years and over; diagnosed with resectable CRC to be followed by adjuvant chemotherapy treatment (chemotherapy group) or no further systemic cancer treatment (surgery group); fluent in spoken and written English sufficient to complete the assessments (based on clinician and/or researcher observations). Exclusion criteria: prior exposure to chemotherapy; significant comorbidities which could affect ability to participate; history of stroke or other brain trauma. All exclusion criteria were identified through medical records or self-report. Eligible patients were identified and approached by a member of the research team at each Hospital. Those interested in participating were contacted by a research assistant by telephone. Participants were contacted by telephone to arrange all subsequent follow-up appointments.

Healthy adult volunteers aged 18 years and over with fluent written and spoken English were recruited from communities within hospital catchment areas.

Assessments were conducted in a private room in the hospital, the University or at the participant's home. All participants provided

written, informed consent. Ethical approval for the study was granted by South West–Cornwall and Plymouth National Health Service Research Ethics Committee (Ref:13/SW/0201).

2.3 | Assessments

Demographic and clinical information were collected at T1. A battery of neuropsychological assessments (NP) was used to assess cognitive function at all three time-points conducted by a trained research assistant. Initial assessment took place in clinic with follow up assessments conducted at the participants home. The battery included the three core measures recommended by the ICCTF¹⁴: the Trail Making Test (TMT A&B),¹⁶ a test of attention, executive function and visuo-motor ability; Hopkins Verbal Learning Test–Revised,¹⁷ a test of verbal memory (immediate and delayed recall, retention and recognition); the Controlled Oral Word Association Test (COWA, phonemic and semantic versions), a test of verbal fluency and executive function.¹⁸ These were supplemented with the Digit Span subtest of the Wechsler Adult Intelligence Scales–Third Edition, (WAIS-III Digit Span), a test of attention and working memory¹⁹; The Symbol Digit Modalities Test (SDMT, written and oral versions),²⁰ a test of attention, visuo-motor ability and concentration; Grooved Pegboard Test (GP, dominant and non-dominant hand), test of fine motor function²¹ and The Benton Visual Retention Test, a test of immediate recall visual memory (number correct and number of errors recorded).²² Depression and anxiety were assessed using the Hospital Anxiety and Depression Scale²³ and fatigue using the Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT-F v4).²⁴ Further details of the methodology can be found in the study protocol.²⁵

A number of steps were taken to minimise potential bias in the study. Both the methods and analyses strictly adhered to the ICCTF guidelines. Standardised neuropsychological tests were administered by trained researchers and alternate forms were used when possible. Tests scores were normed for age and gender and the effects of age, cancer stage and education were controlled in the analyses. The effects of learning were controlled for using data from a learning control group where appropriate. Multiple methods of analysis were used, drop-outs were adjusted for through the use of multilevel modelling, and multiple imputation was used to account for missing data at each time point.

2.4 | Sample size

A sample size calculation was performed using GPower3.1. To detect an effect size of -0.26 with 80% power and a significance level of 0.05 at the final time point, a minimum sample size of 120 participants was indicated. Based on medium effect sizes in a meta-analysis of chemotherapy and cognitive function,² a sample size of 120 would allow effects to be detected in the following domains: executive function, information processing speed, language, motor function, verbal memory and visual memory. However, it is acknowledged small effects may not be detected in the following domains: attention and visuospatial skills. Assuming an overall attrition rate of 22%

(based on SCOT trial [Short Course Oncology Treatment - A Study of Adjuvant Chemotherapy in Colorectal Cancer] attrition rates^{1,26}), a total sample size of 156 participants was sought.

A total of 136 participants were recruited into the study: 78 in the chemotherapy group, 58 in the surgery only group. A breakdown of recruitment is given in the flow chart (Figure 1).

3 | STATISTICAL ANALYSES

Analysis of missing data among all variables of the study was undertaken. Initial analyses determined participants lost to follow-up as a percentage, per group. Thereafter missing data levels per timepoint were ascertained. If missing value levels were $>5\%$ per variable at any timepoint, missing values within a timepoint were multiply imputed ($m = 10$) for each timepoint individually, using available data from all timepoints within the imputation model. Imputation was conducted with the Statistical Product and Service Solutions (IBM-SPSS) Multiple Imputation function using the Markov Chain Monte Carlo Linear algorithm, and limits for maximum and minimum values based on available data. Ten imputations were generated ($m = 10$). Each dataset was used in analyses independently, and thereafter the results of the 10 analyses were combined in the final stage of multiple imputation procedures outlined by Rubin²⁷; Shaefer and Olsen²⁸ and Allison.²⁹ Analyses where adjustments were made for learning effects (see below) were done on a per imputation basis.

Raw scores on each neuropsychological test, for each participant, were standardised by taking the normative population mean score for each test^{18,20,30–34} from participant mean scores and dividing by the population standard deviation (from the same source). Where higher scores were indicative of poorer performance, these scores were reversed so higher standardised scores represented better performance across all tests. Negative standardised scores indicate performance below the population mean and positive scores indicate performance above the population mean.

Composite NP scores for each participant were calculated by taking the mean z-score across 14 tests (the COWA semantic version was not a standardised score therefore excluded), at each timepoint. The mean score across tests rather than a sum was used to retain the original metrics of the standardised scores.

In line with the ICCTF recommendations on reporting analyses based on individual tests scores¹⁴ multiple methods were used to assess change in cognitive performance over time.

3.1 | Calculating the number of scores in deficit/ number of ppt considered in deficit

Two deficit scores (0 = not in deficit; 1 = in deficit) were calculated for each neuropsychological test score; 1.5 SD and 2 SD below the group mean score. The total number of tests in deficit (at a timepoint) for each was calculated for each participant to determine if they were in cognitive impairment as follows. Ingraham and Aiken³⁵ provide useful data on determining criteria for impairment in multiple test batteries.




FIGURE 1 Patient recruitment flowchart.

The present study yielded 15 scores from seven neuropsychological tests. On the basis of 15 tests, when employing the criteria of 2SD below the mean, according to the Ingraham and Aiken³⁵ criteria 30% of the population would be expected to score at least 2SD below the mean on one test out of 15% and 1% of the population would be expected to score 2SD below the mean on at least 3 tests.

3.2 | Learning adjusted difference scores (Adj Δ) between timepoints (Adj Δ T1T2 and Adj Δ T1T3)

For each participant the difference in each test score at follow-up, from the baseline scores was calculated by subtracting baseline z-scores from follow-up z-scores. To generate learning adjusted

difference scores (Adj Δ T1T2 and Adj Δ T1T3), the mean change in the learning control group (representative of natural learning over multiple testing) was subtracted from the individual difference scores of the chemotherapy and surgery participant scores.

3.3 | Residualised change scores

Z-scores for each NP test and composite score were utilised to generate Residualised change scores (RCS) (for each participant), by saving the standardised residuals after predicting follow-up scores from baseline scores using simple linear regression. Independent linear regressions were run for each treatment group (chemotherapy and surgery) and were done for T2 and T3 separately.

3.4 | Reliable change Index (RCI)

The RCI for each NP test was computed utilising Hsu³⁶ method. As with the RCS, this was calculated per treatment group using treatment group-based means, standard deviation and test-retest correlations; and were done for T2 and T3 separately.

Standardised scores (transformed for each NP test), number of tests in deficit, and change scores between timepoints (i.e. learning adjusted difference scores, RCS and RCI between T1 and T2, and T1 and T3) were utilised to perform analyses between groups and over time.

Chi-square (Fisher's exact) tests were used to identify significant differences in the proportion of participants in each group showing a deficit of at least 1.5SD on at least two tests or 2SD on one test at all three timepoints. For group differences in NP indices, continuous measures were examined using *t*-tests (corrected for heterogeneity of variance where necessary). Thereafter, a series of multiply imputed regression analyses were performed to test for group differences (controlling for age, education, and cancer stage) on each of the 15 individual cognitive test scores and the composite score, for standardised scores (at T1, T2 and T3) and for the learning adjusted difference scores, the RCS and the RCI scores for test performance between T1 and T2, and separately for performance between T1 and T3. Finally, to examine changes in each NP score over time by group, a series of multi-level models (MLM) were conducted, using group (surgery plus chemotherapy vs. surgery only) and time (T1 vs T2 vs T3) as main effects and a time by group interaction, also controlling for effects of age, education, cancer stage. Significant effects were explored within effect and across the interaction using post hoc tests on adjusted means ($p < 0.05$ for significance).

4 | RESULTS

Participant characteristics are shown in Table 1. The surgery only group were significantly older than the chemotherapy group. The majority of the chemotherapy group had stage III cancer compared to stage II in the surgery only group. The average number of days to follow-up were 94 from T1 to T2 and 181 from T2 to T3. The group ($N = 55$) recruited to control for learning effects on neuropsychological tests overtime had a mean age of 57.8 years and 60% were female. Z-scores for each neuropsychological test are available in the Supplementary Material (Table S1).

4.1 | Primary objective

4.1.1 | Cognitive domains affected

Deficits, defined as two standard deviations (2SD) below the mean performance, were seen across a broad range of neuropsychological tests. The greatest proportion deficits occurred in motor function (42% of cancer patients), verbal learning (19% cancer patients), and

verbal fluency (14%). A similar pattern was observed when using the 1.5 SD criterion.

4.1.2 | Frequency of cognitive deficits by group

The graph below (Figure 2.) shows the percentage of participants in each cancer group scoring at least two SD below the mean score on at least one test and at least three tests at each timepoint compared to the proportions expected in a normal population due to chance alone.³⁵ Perceptuo-motor (42% scored 2SD below the mean), memory (19% at 2SD) and executive function (16% at 2SD) were the cognitive domains most frequently affected.

At all timepoints both groups showed a greater percentage of participants with deficits on both one and three tests than would be expected by chance in the normal population. A similar pattern was observed when using the 1.5SD criterion.

Visual inspection suggests that by T3 the proportion of patients showing impaired performance on either criterion had decreased.

Chi-squared tests computed to identify significant differences in the proportion of participants in each group showing a deficit showed no significant group differences at any timepoint (Supplementary Table S9). No group differences in change in neuropsychological test scores were found at any timepoints using learning adjusted change scores, RCI, and RCS (Supplementary Tables S2a-c to S8).

4.1.3 | Change in cognitive performance over time

Supplementary Table S10 presents the results of an MLM exploring changes in neuropsychological test performance in each group over time controlling for age, education and cancer stage. Of particular note is the time by group interaction effect significant at the $p < 0.05$ level for the composite neuropsychological test score. Post-hoc tests showed that the groups did not significantly differ within each timepoint ($p > 0.05$); however, while the chemotherapy group did not show significant differences between T1, T2 or T3 in pairwise comparisons ($p > 0.05$), the surgery only group showed significant increases in scores between T1 and T3 ($p = 0.017$) and T2 and T3 ($p < 0.001$). This suggests that the surgery only group showed an improvement in test performance over time, while the chemotherapy group showed no improvement (See Figure 3).

4.2 | Secondary objective

4.2.1 | Cognition, mood and fatigue

Pearson's correlations were performed between composite neuropsychological score and depression, anxiety and fatigue at all time points. The relationship between mood, fatigue and cognition was not strong, with weak correlations found between fatigue and cognition

TABLE 1 Participant characteristics by group at baseline assessment.

	Total (95% CI) (%) N = 136	Chemotherapy group (95% CI) (%) N = 78	Surgery group (95% CI) (%) N = 58	Group differences t/chi (p value)
Characteristic				
Gender	191	78	58	
Men	91 (47.6)	41 (52.6)	28 (48.3)	
Women	100 (52.4)	37 (47.4)	30 (51.7)	$\chi^2 = 0.245$ (p = 0.621)
Age	61.3 (59.5, 63.2)	60.2 (57.5, 63.0)	66.1 (62.9, 69.3)	t = 2.595 (p = 0.004)
Highest level of education attained				
Primary	1 (0.5)	0	0	
Secondary—lower	33 (17.2)	13 (16.7)	14 (24.1)	
Secondary—higher (16+)	29 (15.2)	16 (20.5)	8 (13.8)	
Higher education—cert/dip	44 (23)	21 (26.9)	16 (27.6)	
Degree	55 (28.8)	15 (19.2)	16 (27.6)	
Masters	23 (12.0)	9 (11.5)	3 (5.2)	
Doctoral	6 (3.1)	4 (5.1)	1 (1.7)	$\chi^2 = 5.387$ (p = 0.371)
Tumour stage (frequency)				
Stage I	16 (12.0)	2 (2.9)	14 (24.1)	
Stage II	57 (41.8)	19 (24.6)	38 (64.8)	$\chi^2 = 53.350$ (p < 0.0001)
Stage III	62 (45.3)	56 (71.2)	6 (10.5)	
Stage IV	1 (1.0)	1 (1.3)	0 (0.5)	
Chemotherapy regimen (%)				
FOLFOX/OxMdG (folinic acid + fluorouracil + Oxaliplatin)	NA	24 (32)	NA	
Xelox/CapOx (Oxaliplatin + capecitabine)	NA	25 (34)	NA	
Xeloda (capecitabine)	NA	12 (16)	NA	
5FU/de gramont or modified de gramont: Fluorouracil	NA	13 (18)	NA	
Marital status				
Never married	27 (14.1)	12 (15.4)	10 (17.2)	
Married/Civil partnership/Cohabiting	123 (64.4)	49 (62.8)	29 (50)	
Separated, divorced, or formerly in civil partnership	25 (13.1)	12 (15.4)	10 (17.2)	$\chi^2 = 3.775$ (p = 0.287)
Widowed or surviving partner from civil partnership	16 (0.4)	5 (6.4)	9 (15.5)	
Number of comorbidities				
0	67 (35.1)	22 (28.2)	20 (34.5)	
1	58 (30.4)	23 (29.5)	19 (32.6)	
2	36 (18.8)	15 (19.2)	12 (20.7)	$\chi^2 = 2.853$ (p = 0.583)
3	15 (7.9)	9 (11.5)	4 (6.9)	
4	14 (7.3)	9 (11.5)	3 (5.2)	
7	1 (0.5)	0	0	

TABLE 1 (Continued)

	Mean (standard deviation) T1 N = 136	Mean (standard deviation) T1 N = 78 Chemotherapy group	Mean (standard deviation) T1 N = 58 Surgery group	Group differences t/chi (p value)
Total				
HADS-Depression T1	4.30 (3.52)	4.28 (3.33)	4.33 (3.78)	$t = 0.074$ ($p = 0.941$)
HADS-Anxiety T1	6.05 (4.31)	6.18 (4.31)	5.88 (4.35)	$t = -0.400$, ($p = 0.690$)
FACT-Fatigue T1	36.55 (11.27)	36.10 (11.356)	37.15 (1.21)	$t = 0.536$, ($p = 0.593$)
	Mean (standard deviation) T2 N = 108	Mean (standard deviation) T2 N = 66 Chemotherapy group	Mean (standard deviation) T2 N = 42 Surgery group	Group differences t/chi (p value)
Total				
HADS-Depression T2	3.85 (2.87)	5.09 (2.12)	2.95 (2.63)	$t = -3.823$ ($p < 0.001$)
HADS-Anxiety T2	5.37 (3.551)	5.39 (3.95)	5.10 (3.67)	$t = -0.390$ ($p = 0.349$)
FACT-Fatigue T2	37.42 (11.15)	30.92 (11.17)	41.35 (9.95)	$t = 4.888$ ($p < 0.001$)
	Mean (standard deviation) T3 N = 88	Mean (standard deviation) T3 N = 53 Chemotherapy group	Mean (standard deviation) T3 N = 35 Surgery group	Group differences t/chi (p value)
Total				
HADS-Depression T3	3.53 (3.04)	4.22 (3.06)	3.37 (3.24)	$t = -1.214$ ($p = 0.117$)
HADS-Anxiety T3	5.22 (3.89)	5.68 (4.36)	4.37 (3.61)	$t = -1.444$ ($p = 0.076$)
FACT-Fatigue T3	39.93 (11.56)	36.74 (13.54)	41.38 (10.23)	$t = 1.695$ ($p = 0.47$)

Note: T1—approx. 4 weeks post-surgery, prior to chemotherapy. T2—12 weeks after first scheduled chemotherapy (approx. 4 months post-surgery). T3—3 months after last scheduled chemotherapy for patients receiving 6 months of treatment or 6 months after last scheduled chemotherapy for patients receiving 3 months of treatment (approx. 10 months post-surgery). t = t-value and X^2 = chi square statistic.

Abbreviations: FACT, Functional Assessment of Cancer Therapy - Fatigue; HADS, Hospital Anxiety and Depression Scale.




FIGURE 2 Percentage of participants in each group scoring at least 2 standard deviations below the mean on at least one and at least three neuropsychological tests at each timepoint shown with the expected percentage in a normal population.

SD=standard deviation, Expected=percentage of the general population expected to score at least 2SD below the mean (Ingraham & Aiken, 1996)

T1 - approx. 4 weeks post-surgery, prior to chemotherapy (Chemotherapy group N=78, Surgery group N=58)

T2 - twelve weeks after first scheduled chemotherapy (approx. 4 months post-surgery) (Chemotherapy group N=66, Surgery group N=42)

T3 - three months after last scheduled chemotherapy for patients receiving six months of treatment or six months after last scheduled chemotherapy for patients receiving three months of treatment (approx. 10 months post-surgery) (Chemotherapy group N=53, surgery group N=35)




FIGURE 3 Composite neuropsychological test score over time by group.

at T2 ($r = 0.183$, $p < 0.023$) and T3 ($r = 0.238$, $p = 0.010$). Greater depression was correlated with poorer cognition at T3 (-0.273 , $p = 0.003$) only. This pattern was repeated in individual group analyses. Between group analyses of depression, anxiety and fatigue revealed that the chemotherapy group experienced significantly more depression and fatigue at T2 than the surgery only group (Table 1). Depression ($F_{[2]} = 3.339$, $p = 0.040$) and fatigue ($F_{[2]} = 7.676$, $p < 0.001$) were found to significantly worsen at T2 in the chemotherapy group. No other differences in anxiety, depression and fatigue overtime were found in either group.

5 | DISCUSSION

The present study examined the impact of chemotherapy on cognitive recovery post-surgery in CRC patients by comparing those who received chemotherapy after surgery and those who did not. The proportion of cancer patients in both groups demonstrated much higher deficits in cognitive function than would be expected in the normal population. The proportion with impaired scores (one test at 2SD) was similar to those found in previous CRC research (47%–67%).¹²

Although both groups demonstrated deficits in cognitive function there were no differences in cognitive performance between groups at any timepoints consistent with previous research in breast cancer.¹⁰ However, the MLM analysis found that the surgery only group, despite being older, showed a greater improvement in overall cognitive performance over time than the chemotherapy group. This finding suggests that while the observed cognitive deficits in both groups are likely attributable to the effects of surgery, and/or the cancer itself¹¹ the addition of chemotherapy may slow post-surgical cognitive recovery.

This dual impact of surgery and chemotherapy may explain the inconsistent research findings regarding the effect of chemotherapy

on cognition to date.⁵ Research has shown no effect of chemotherapy on cognition¹² and poorer cognition in CRC patients having chemotherapy.¹³ A larger sample assessed over a longer time frame is required to tease out the effects of chemotherapy and surgery and the potential role of some other element of the cancer process.

Consistent with prior research¹² there was little association between mood, fatigue and cognition supporting the assertion that the observed deficits were attributable to surgery. The chemotherapy group showed greater depression and fatigue than the surgery only group during chemotherapy, but these differences reduced post chemotherapy.

The results indicate that interventions aimed at supporting patients and reducing the impact of cognitive deficits should not be limited to those undergoing chemotherapy.³⁷

5.1 | Study limitations

While the use of a consecutive series of patients from multiple sites allows these findings to be generalised to the wider CRC population, the study is not without limitations. These include the small sample size and expected loss to follow-up. Recruitment was challenging, patients were approached whilst recovering from surgery and a large proportion declined to participate (59%). This may have caused sampling biases and limited the statistical power to detect differences between the patient groups. Baseline assessment took place in clinic with subsequent assessments at the participants home. The potential impact of context specific learning should be considered.³⁸ It was not possible to analyse different treatment regimens on cognitive performance, as these were too varied and any analyses would have limited statistical power. A substantial loss of follow-up was found (up to 40%) with many participants reporting wanting to

move forward with life, deteriorating health, complications, multiple healthcare appointments, and return to work and usual routine acting as barriers to participation. However, the use of covariates and MLM in the statistical analysis increased the power and partially mitigated the reduced sample size.

Despite these limitations this paper reports one of the few longitudinal studies of cognitive impairment in patients with CRC whilst controlling for learning effects and including a pre-chemotherapy cognitive function baseline. The study closely adhered to the ICCTF guidelines for both assessment and analysis, increasing the robustness of the findings and allowing cross-study comparison.

5.2 | Clinical implications

CRC patients undergoing surgery, regardless of chemotherapy status, should be monitored for cognitive difficulties and support and appropriate referral made for those with impairment which impacts their daily functioning.

6 | CONCLUSIONS

This study confirms the presence of objective cognitive impairment up to 10 months after surgery in people with CRC. Those not undergoing chemotherapy showed greater recovery over time. Further follow-up of this cohort will enable a better understanding of the long-term trajectory of cognitive impairment following surgery for CRC. There is now adequate evidence to suggest the need for supportive cognitive interventions for those undergoing treatment for CRC.

AUTHOR CONTRIBUTIONS

Marie-Rose Dwek contributed to the design of the study, data collection and drafted the manuscript. Stanton P. Newman contributed to the design of the study, analysis of the data and drafted the manuscript. Stefano Brini contributed to analysis of the data and reviewed the manuscript. Pru Holder contributed to data collection and reviewed the manuscript. Michael Machesney contributed to the design and conduct of the study and reviewed the manuscript. David Propper contributed to the design and conduct of the study and reviewed the manuscript. Lorna R. Rixon contributed to the design of the study, data collection and reviewed the manuscript. Shashivadan P. Hirani contributed to the design of the study, analysis of the data and drafted the manuscript. Catherine S. Hurt contributed to the design of the study, analysis of the data and drafted the manuscript.

ACKNOWLEDGEMENTS

The authors would like to thank Barts Charity for funding the present research and the patients who gave up their time to participate in the research. This study was funded by an award from Barts Charity (477/2313). The funders played no role in the design and conduct of the study and did not contribute to the writing of the paper.

CONFLICT OF INTEREST STATEMENT

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ETHICS STATEMENT

Ethical approval for the study was granted by South West-Cornwall and Plymouth NHS Research Ethics Committee (Ref: 13/SW/0201).

ORCID

Catherine S. Hurt  <https://orcid.org/0000-0003-1571-0040>

ENDNOTE

¹ Personal communication with Dr Bridgewater of University College London Hospital.

REFERENCES

1. UK CR. Bowel Cancer Survival Statistics; 2014. [cited 2019 30/8/19]. <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer/survival>
2. Hodgson KD, Hutchinson AD, Wilson CJ, Nettelbeck T. A meta-analysis of the effects of chemotherapy on cognition in patients with cancer. *Cancer Treat Rev*. 2013;39(3):297-304. <https://doi.org/10.1016/j.ctrv.2012.11.001>
3. Zhang Y, Bao H-G, Lv Y.-L, et al. Risk factors for early postoperative cognitive dysfunction after colorectal surgery. *BMC Anesthesiol*. 2019;19(1):6. <https://doi.org/10.1186/s12871-018-0676-4>
4. NICE. Colorectal Cancer Diagnosis and Management; 2014. [cited 2019 30/8/19]. <https://www.nice.org.uk/guidance/cg131/chapter/1-Recommendations#management-of-local-disease>
5. Chan YN, Leak Bryant A, Conklin JL, Girdwood T, Piepmeier A, Hirschey R. Systematic review of cognitive impairment in colorectal cancer survivors who received chemotherapy. *Oncol Nurs Forum*. 2021;48(6):634-647. <https://doi.org/10.1188/21.onf.634-647>
6. Cerulla Torrente N, Navarro Pastor J-Bde la Osa Chaparro N. Systematic review of cognitive sequelae of non-central nervous system cancer and cancer therapy. *J Cancer Surviv*. 2020;144(4):464-482. <https://doi.org/10.1007/s11764-020-00870-2>
7. Vardy JL, Dhillon HM. "Mind the gaps": cognition and cancer. *Psycho Oncol*. 2018;27(1):10-12. <https://doi.org/10.1002/pon.4582>
8. Dijkshoorn ABC, van Stralen HE, Sloots M, Schagen SB, Visser-Meily JMA, Schepers VPM. Prevalence of cognitive impairment and change in patients with breast cancer: a systematic review of longitudinal studies. *Psycho Oncol*. 2021;30(5):p635-p648. <https://doi.org/10.1002/pon.5623>
9. Hwang SY, Kim K, Ha B, et al. Neurocognitive effects of chemotherapy for colorectal cancer: a systematic review and a meta-analysis of 11 studies. *J Korean Cancer Assoc*. 2021;53(4):1134-1147. <https://doi.org/10.4143/crt.2020.1191>
10. Bernstein LJ, McCreath GA, Komeylian Z, Rich JB. Cognitive impairment in breast cancer survivors treated with chemotherapy depends on control group type and cognitive domains assessed: a multilevel meta-analysis. *Neurosci Biobehav Rev*. 2017;83:417-428. <https://doi.org/10.1016/j.neubiorev.2017.10.028>

11. Chan A, Cheng I, Wang C, et al. Cognitive impairment in adolescent and young adult cancer patients: pre-treatment findings of a longitudinal study. *Cancer Med*. 2022;12(4):4821-4831. Epub ahead of print. PMID: 36221816. <https://doi.org/10.1002/cam4.5295>
12. Vardy JL, Dhillon HM, Pond GR, et al. Cognitive function in patients with colorectal cancer who do and do not receive chemotherapy: a prospective, longitudinal, controlled study. *J Clin Oncol*. 2015; 33(34):4085-4092. <https://doi.org/10.1200/jco.2015.63.0905>
13. Sales MVC, Suemoto CK, Apolinario D, et al. Effects of adjuvant chemotherapy on cognitive function of patients with early-stage colorectal cancer. *Clin Colorectal Cancer*. 2019;18(1):19-27. <https://doi.org/10.1016/j.clcc.2018.09.002>
14. Wefel JS, Vardy J, Ahles T, Schagen SB. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. *Lancet Oncol*. 2011;12(7): 703-708. [https://doi.org/10.1016/s1470-2045\(10\)70294-1](https://doi.org/10.1016/s1470-2045(10)70294-1)
15. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. *Int J Surg Lond Engl*. 2014;12(12):1495-1499. <https://doi.org/10.1016/j.ijsu.2014.07.013>
16. Reitan RM. *Neuropsychological Test Battery*. Reitan Neuropsychology Laboratory; 1955.
17. Benedict RHB, Schretlen D, Groninger L, Brandt J. Hopkins verbal learning test—revised: normative data and analysis of inter-form and test-retest reliability. *Clin Neuropsychol*. 1998;12(1):43-55. <https://doi.org/10.1076/clin.12.1.43.1726>
18. Ruff RM, Light RH, Parker SB, Levin HS. Benton controlled oral word association test: reliability and updated norms. *Archives Clin Neuropsychol*. 1996;11(4):329-338. <https://doi.org/10.1093/arclin/11.4.329>
19. Wechsler D. *Wechsler Intelligence Scale for Children (WISC-III): Manual*. 3rd ed. The Psychological Corporation; 1991.
20. Sheridan LK, Fitzgerald HE, Adams KM, et al. Normative symbol digit modalities Test performance in a community-based sample. *Archives Clin Neuropsychol*. 2006;21(1):23-28. <https://doi.org/10.1016/j.acn.2005.07.003>
21. Matthews C Klove H. *Instruction Manual for the Adult Neuropsychology Test Battery*. University of Wisconsin Medical School; 1964.36.
22. Sivan AB. *Benton Visual Retention Test*. 5th ed. The Psychological Corporation; 1992.
23. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand*. 1983;67(6):361-370. <https://doi.org/10.1111/j.1600-0447.1983.tb09716.x>
24. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. *J Pain Symptom Manag*. 1997;13(2):63-74. [https://doi.org/10.1016/s0885-3924\(96\)00274-6](https://doi.org/10.1016/s0885-3924(96)00274-6)
25. Dwek MR, Rixon L, Simon A, Hurt C, Newman S. Examining the effects of adjuvant chemotherapy on cognition and the impact of any cognitive impairment on quality of life in colorectal cancer patients: study protocol. *BMC Psychol*. 2015;3(1):43. <https://doi.org/10.1186/s40359-015-0100-5>
26. Iveson TJ, Kerr RS, Saunders MP, et al. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. *Lancet Oncol*. 2018;19(4):562-578. [https://doi.org/10.1016/s1470-2045\(18\)30093-7](https://doi.org/10.1016/s1470-2045(18)30093-7)
27. Rubin DB. *Multiple Imputation for Nonresponse in Surveys*. John Wiley & Sons, Inc; 1987. Wiley Series in Probability and Statistics.
28. Schafer JL, Olsen MK. Multiple imputation for multivariate missing-data problems: a data analyst's perspective. *Multivariate Behav Res*. 1998;33(4):545-571. https://doi.org/10.1207/s1532790mbr3304_5
29. Allison PD. Multiple imputation for missing data: a cautionary tale. *Socio Methods Res*. 2000;28(3):301-309. <https://doi.org/10.1177/0049124100028003003>
30. Tombaugh T. Trail making test A and B: normative data stratified by age and education. *Archives Clin Neuropsychol*. 2004;19(2):203-214. [https://doi.org/10.1016/s0887-6177\(03\)00039-8](https://doi.org/10.1016/s0887-6177(03)00039-8)
31. Funes C, Rodriguez H, Lopez S. Norm comparisons of the Spanish-language and English-language WAIS-III: implications for clinical assessment and test adaptation. *Psychol Assess*. 2016;28(12): 1709-1715. <https://doi.org/10.1037/pas0000302>
32. Youngjohn J, Larrabee G, Crook T. New adult age-and education-correction norms for the benton visual retention test. *Clin Neuropsychol*. 1993;7(2):155-160. <https://doi.org/10.1080/13854049308401517>
33. Brandt J, Benedict R. *Hopkins Verbal Learning Test-Revised (HVLt-R) Professional Manual*. Lutz, FL; 2001.
34. Ruff R, Parker S. Gender-and age-specific changes in motor speed and eye-hand coordination in adults: normative values for the Finger Tapping and Grooved Pegboard Tests. *Percept Mot Ski*. 1993;76(3_Suppl 1):1219-1230. <https://doi.org/10.2466/pms.1993.76.3c.1219>
35. Ingraham LJ, Aiken CB. An empirical approach to determining criteria for abnormality in test batteries with multiple measures. *Neuropsychology*. 1996;10(1):120-124. <https://doi.org/10.1037/0894-4105.10.1.120>
36. Hsu L. Caveats concerning comparisons of change rates obtained with five methods of identifying significant client changes: comment on Speer and Greenbaum. *J Consult Clin Psychol*. 1999;67(4): 594-598. <https://doi.org/10.1037/0022-006x.67.4.594>
37. Kim Y, Kang SJ. Computerized programs for cancer survivors with cognitive problems: a systematic review. *J Cancer Surviv*. 2019; 13(6):911-920. <https://doi.org/10.1007/s11764-019-00807-4>
38. Godden DR, Baddeley AD. Context-dependent memory in two natural environments: on land and underwater. *Br J Psychol*. 1975;66(3): 325-331. <https://doi.org/10.1111/j.2044-8295.1975.tb01468.x>

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Dwek M-R, Newman SP, Brini S, et al. The impact of chemotherapy on cognitive performance post-surgery in patients with colorectal cancer: a prospective cohort study. *Psychooncology*. 2023;1-10. <https://doi.org/10.1002/pon.6147>